Please join PPMD and REGENXBIO on Wednesday, November 20th at 1 p.m. E.T. for a community webinar, “RGX-202: AFFINITY DUCHENNE Pivotal Program and Functional Data.” REGENXBIO will provide an update on its AFFINITY DUCHENNE trial of RGX-202, a next-generation microdystrophin gene therapy. REGENXBIO’s Dr. Naz Dastgir will discuss the company’s pivotal trial plans and share interim clinical data, including the first functional data for RGX-202.
Submit questions in advance here.
Register for the webinar here.
